OncoViews
@OncoViews
Followers
2K
Following
3K
Media
399
Statuses
4K
Uniting HCPs to share the latest advances in #oncology. Making medical education accessible to all. Content on this channel is for informational purposes only.
Joined March 2020
As we wrap up the year on OncoViews, we’re grateful for our incredible OncoViewers and experts who make medical education accessible and impactful 🧑⚕️👩⚕️. Together, we’ve shared knowledge and advanced the conversation in oncology. Here’s to continuing the journey in 2025!.
1
8
11
RT @LungSummit: How can we optimize EGFR-targeted therapy outcomes while maintaining the highest standards of patient safety?. Join @DrJNai….
0
3
0
RT @DrJNaidoo: SCLC transformation from EGFR+ NSCLC, outcomes & tx? @ESMO_Open:. - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+IC….
0
29
0
RT @LungSummit: Have a patient case in NSCLC?. Submit your case or questions to our experts @GautschiOliver, @DrJNaidoo, and @nicogirardcur….
0
6
0
RT @LungSummit: Join @GautschiOliver for an expert-led talk on evolving targeted therapies in NSCLC. Explore ALK+ & EGFR+ challenges, res….
0
5
0
RT @LungSummit: How close are we to using SCLC subtypes to guide treatment? . @sands_jacob explains why subtyping is still experimental, bu….
0
5
0
RT @LungSummit: What���s the role of anti-CTLA-4 in #NSCLC patients with brain metastases? . Hear @JordiRemon share his current approach and….
0
12
0
RT @LungSummit: 📢 We're excited to welcome you today at 5:30 PM CEST for a deep dive into IO in #NSCLC. @peters_solange, @FordePatrick &….
0
8
0
RT @LungSummit: On our next roundtable @DrJNaidoo focuses on synergy in EGFR+ NSCLC by highlighting latest combination strategies with chem….
0
7
0
RT @LungSummit: Our chair @GautschiOliver opens the roundtable with an expert analysis of ALK+ and EGFR+ NSCLC. Together with @DrJNaidoo an….
0
7
0
RT @LungSummit: 🔔 Save the Date! . Join our faculty @GautschiOliver, @DrJNaidoo and @nicogirardcurie for a focused update on targeted thera….
0
8
0
RT @LungSummit: Two checkpoint inhibitors in #SCLC got approved in Europe based on data from Asian populations only. Does it matter and whi….
0
10
0
RT @LungSummit: 🚨 TODAY . Don't miss today's roundtable on the latest progress in treating small cell lung cancer with renowned experts, @p….
0
7
0
RT @LungSummit: Got an #NSCLC case or a question on immunotherapy? Share it anonymously and get expert input during our upcoming session wi….
0
5
0
RT @LungSummit: How do leading thoracic oncologists address the challenges of #SCLC in both limited- and extensive-stage disease?. Join @sa….
0
4
0
RT @LungSummit: Still unsure how to optimize IO in resectable #NSCLC? 🫁. Join @JordiRemon as he tackles unanswered questions, alongside @pe….
0
9
0
RT @LungSummit: Meet this year's global faculty behind the #ILCS!. 🌍 From the US to Singapore, Europe to Australia – leading experts will s….
0
5
0
RT @LungSummit: How do we proceed following ASCO with IO in early-stage #NSCLC? 🫁. Don’t miss the live debate with @FordePatrick and @Jordi….
0
3
0
RT @LungSummit: How do we maximize outcomes with IO combinations in #NSCLC? Join @peters_solange as she discusses the latest evidence and o….
0
5
0
RT @LungSummit: Registration is now open for the 7th International Lung Cancer Summit #ILCS25! Connect with our hosts, @Alfdoc2 & @peters_s….
0
8
0
RT @LungSummit: Registration opens on 1 June for the 7th International Lung Cancer Summit #ILCS25! . Join our hosts, @Alfdoc2 & @peters_sol….
0
8
0